AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00188331 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological Testing
Description: neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
Study NCT03694730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Treatment
Description: Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
Study NCT03694730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment
Description: Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
Study NCT03694730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain- Guided Activity Modification
Description: Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
Study NCT04527744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the injection of onabotulinumtoxinA at different point
Description: For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
Study NCT04527744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the injection of onabotulinumtoxinA at different point
Description: For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
Study NCT04083079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
Study NCT04083079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhG-CSF
Description: Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
Study NCT02810743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ddAC-CP-Olaparib
Description: ddAC-CP-Olaparib
Study NCT02810743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ddAC-mini CTC
Description: ddAC - mini CTC
Study NCT02233946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-facilitated brief intervention
Description: Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
Study NCT01918722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICH-1(herbal medicine with Hirudo, Tabanus)
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
Study NCT01918722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo herbal medicine, one dose,bid, for 10 days
Study NCT01918722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICH-2(herbal medicine without Hirudo, Tabanus)
Description: (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
Study NCT04223596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib 90 mg for the first 7 days (D1-7 at cycle 1) and then 180 mg daily thereafter for QW4 cycles of duration (28 days+-3 days)
Study NCT02272465 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study
Study NCT02510066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
Study NCT02510066 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
Study NCT01764386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB
Description: Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
Study NCT01764386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLI
Description: The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
Study NCT01764386 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual Care is a self-directed lifestyle intervention program
Study NCT00740662 — intervention group
Intervention type: PROCEDURE
Intervention: Distal gastric bypass
Description: Distal gastric bypass
Study NCT03589924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate IBBR+TiLoop®Bra
Description: Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
Study NCT03589924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate-delayed IBBR+TiLoop®Bra
Description: Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
Study NCT02748512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAI Insert administered using the Mk II inserter
Study NCT02748512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAI Insert administered using the Mk I inserter
Study NCT01426815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
Study NCT01426815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
Study NCT02990728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
Study NCT02990728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena®
Study NCT02990728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena®
Study NCT01314092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured adipose derived stem cells(low dose group)
Description: low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
Study NCT01314092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cultured adipose derived stem cells(high dose group)
Description: high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
Study NCT04187911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Developmental Psychotherapy (DDP)
Description: DDP involves approximately twenty 1 hour sessions (usually over 6-9 months) with the adoptive parent/foster carer and child, facilitated by a specifically trained therapist. The role of the therapist during sessions is to maintain an attuned relationship with both child and parent - modelling and encouraging development of a similarly attuned relationship between the child and parent. Therapists are trained to use Playfulness, Acceptance, Curiosity and Empathy (PACE). Our research suggests that key mechanisms of action in DDP might include the active participation of the parents and increased carer empathy and emotional warmth for the child. DDP experts believe this helps build parental capacity for attuned dialogue with the child, co-creation of the meanings underlying child behaviour, and co-regulation of experienced emotions aiming to address four main problem areas: 1. child emotional regulation 2. parental stress 3. the parent-child relationship 4. child mental health.
Study NCT04187911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual (SAU)
Description: SAU tends to be case-dependent with therapists and social workers attempting to respond to the sometimes changeable needs of the family as needs arise. At the time of our UK mapping and modelling work, these services were usually CAMHS based. This may have changed, at least for adoptive families, with the advent of the Adoption Support Fund, which, since May 2015, has allowed local authorities / adoption agencies to apply for funding for essential therapeutic services. A wide range of interventions, many with a scant evidence base, have been purchased - sometimes from private practitioners - since 2015. In addition, relevant NICE guidelines, particularly those on Looked After and Accommodated Children, Attachment and Child Abuse and Neglect, have been published or updated.Our detailed qualitative and quantitative process evaluation throughout all study Phases will be crucial to carefully characterise SAU in all study sites.
Study NCT03140293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection
Description: Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
Study NCT03140293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gebauer Ethyl Chloride Spray
Description: Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
Study NCT03244137 — intervention group
Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: See group description.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02264574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
Study NCT02264574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydroxychloroquine
Description: Dispensed according to the local practice.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Dispensed according to the local practice.
Study NCT03465800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delayed lump sum incentives
Description: delayed lump sum payments for physical activity
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Dispensed according to the local practice.
Study NCT02264574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
Study NCT03405298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material
Description: Educational material is in the form of a brochure
Study NCT03405298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Collaborative Care
Description: Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
Study NCT01999660 — intervention group
Intervention type: DEVICE
Intervention: SpaceOAR™ implantation
Study NCT01349855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
Study NCT01587833 — intervention group
Intervention type: DRUG
Intervention: Benzodiazepine (BZD) use, defined by ATC codes
Description: BZD prescription during the study period between January 1, 2001 and December 31, 2009
Study NCT02616354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
Study NCT02616354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imipenem
Description: Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
Study NCT02644538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIFN alfa-2a
Description: chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA \<1000copies/ml, and HBsAg\<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
Study NCT04236713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention 1
Description: Limiting dietary exposure to ethylenediaminetetraacetic acid, erythorbate, propionate and related food additives; limiting eating out to a maximum of 2 days per week.
Study NCT04236713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention 2
Description: Limiting dietary exposure to nitrites, sulfites and related food additives; limiting eating out to a maximum of 2 days per week; limiting drinking wine to a maximum of 2 days per week.
Study NCT00641953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMX-150
Description: (0.3%) 0.5g topically BID to each foot for 4 weeks
Study NCT00641953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMX-150
Description: (0.6%) 0.5g topically BID to each foot for 4 weeks
Study NCT00641953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 g topically BID to each foot for 4 weeks
Study NCT03756779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Dietary intervention with dietary modification of fat intake.
Study NCT03756779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention with dietary modification of fat intake.
Study NCT01409226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3.0-T MRI
Description: Participants undergo MRI prior to biopsy.
Study NCT01409226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Participants undergo breast biopsy after 3.0-T MRI.
Study NCT02274246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadobutrol
Description: Gadobutrol administration in healthy volunteers
Study NCT02162940 — intervention group
Intervention type: OTHER
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.
Study NCT02162940 — intervention group
Intervention type: OTHER
Intervention: The SF 36 test
Description: The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Dispensed according to the local practice.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sulfasalazine
Description: Dispensed according to the local practice.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Description: Dispensed according to the local practice.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: leflunomide
Description: Dispensed according to the local practice.
Study NCT01709578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: Dispensed according to the local practice.
Study NCT04333771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Study NCT00350532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
Study NCT00183573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: 15-20 minute, motivational one-on-one counseling
Study NCT00183573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Informational Intervention
Description: 15 minute informational DVD on safer sex
Study NCT04333771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Study NCT04766827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
Study NCT04766827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel
Description: Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the incidence of allergic reactions, and reducing the toxicity of the drug.
Study NCT02640040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: llizarov external fixation device
Description: llizarov external fixation device was applied to fix the tibia.
Study NCT02640040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intramedullary rod fixation
Description: retrograde intramedullary rod was applied to stabilize the tibia.
Study NCT02640040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
Study NCT00494065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.